Improving Veteran Access to Treatment for Hepatitis C Virus Infection
Dr. Fleming, Dr. Ifeachor, and Dr. Andres are clinical pharmacy specialists; Dr. Reese is the chief of medicine and an internal medicine and infectious disease physician; Ms. Davis is a licensed clinical social worker; Dr. Liangpunsakul is an internal medicine and gastroenterology/hepatology physician; and Dr. White is assistant chief of pharmacy service, all at Richard L. Roudebush VAMC in Indianapolis, Indiana. Dr. Liangpunsakul also is an associate professor of medicine, biochemistry, and molecular biology at Indiana University School of Medicine in Indianapolis. Dr. Ruoff was formerly a clinical pharmacy specialist at Richard L. Roudebush VAMC and currently practices as a clinical pharmacy specialist at VA Great Lakes Healthcare System in Green Bay, Wisconsin.
Author disclosures
This study was supported in part by a Hepatitis Innovation Team (HIT) grant to the hepatitis C care team at the Richard L. Roudebush VAMC and by VA Merit Award 1I01CX000361-01 to Dr. Liangpunsakul from the VA Office of Research and Development.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.